# Philippe Moreau

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philippe-moreau/

## Facts

| Field | Value |
| --- | --- |
| Citations | 103,547 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 153 |
| i10-index | 879 |
| Last Known Institution | Centre National de la Recherche Scientifique |
| OpenAlex ID | https://openalex.org/A5103143602 |
| ORCID iD | https://orcid.org/0000-0003-1780-8746 |
| Works | 2,099 |

## Researcher papers

Showing 12 of 19.

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis](https://scholariq.org/papers/definition-of-organ-involvement-and-treatment-response-in-immunoglobulin-light/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/ide-cel-or-standard-regimens-in-relapsed-and-refractory-multiple-myeloma/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis](https://scholariq.org/papers/high-dose-melphalan-versus-melphalan-plus-dexamethasone-for-al-amyloidosis/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Centre National de la Recherche Scientifique](https://scholariq.org/institutions/centre-national-de-la-recherche-scientifique/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.